Skip to main content
SpringerLink
Log in

Cardiovascular Effects of Cancer Therapy

  • Chapter
Survivors of Childhood and Adolescent Cancer

Part of the book series: Pediatric Oncology ((PEDIATRICO))

Abstract

During the past 40 years, advances in cancer treatment have drastically improved survival rates for children with cancer. Of the 325,000 childhood cancer survivors in the United States, 24 % have survived greater than 30 years from diagnosis. This growing population of survivors brings the wide array of potential late effects of cancer therapy to light. The developing cardiovascular system is particularly vulnerable to cardiotoxic cancer therapies such as anthracyclines and radiation. These treatment modalities have been found to result in chronic, progressive cardiac dysfunction occurring months to decades after treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mariotto AB, Rowland JH, Yabroff KR et al (2009) Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 18:1033–1040

    Article  PubMed  Google Scholar 

  2. Meadows AT, D’Angio GJ (1974) Late effects of cancer treatment: methods and techniques for detection. Semin Oncol 1:87–90

    CAS  PubMed  Google Scholar 

  3. Lipshultz SE, Lipsitz SR, Sallan SE et al (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629–2636

    Article  CAS  PubMed  Google Scholar 

  4. Reulen RC, Winter DL, Frobisher C et al (2010) Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304:172–179

    Article  CAS  PubMed  Google Scholar 

  5. Tukenova M, Guibout C, Hawkins M et al (2011) Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood. Int J Radiat Oncol Biol Phys 80:339–346

    Article  PubMed  Google Scholar 

  6. Scwartz CL (1999) Long-term survivors of childhood cancer: the late effects of therapy. Oncologist 4:45–54

    Google Scholar 

  7. Goldberg JM, Scully RE, Sallan SE et al (2012) Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 34:395–397

    Article  PubMed Central  PubMed  Google Scholar 

  8. Meacham LR, Chow EJ, Ness KK et al (2010) Cardiovascular risk factors in adult survivors of pediatric cancer–a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 19:170–181

    Article  PubMed Central  PubMed  Google Scholar 

  9. Oeffinger KC, Adams-Huet B, Victor RG et al (2009) Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 27:3698–3704

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Meacham LR, Sklar CA, Li S et al (2009) Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med 169:1381–1388

    Article  PubMed Central  PubMed  Google Scholar 

  11. Garmey EG, Liu Q, Sklar CA et al (2008) Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 26:4639–4645

    Article  PubMed Central  PubMed  Google Scholar 

  12. Lipshultz SE, Sallan SE (1993) Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11:1199–1203

    CAS  PubMed  Google Scholar 

  13. Lipshultz SE, Colan SD (2004) Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 22:769–773

    Article  PubMed  Google Scholar 

  14. Lipshultz SE (2006) Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 33:S8–S14

    Article  CAS  PubMed  Google Scholar 

  15. Lipshultz SE (2007) Heart failure in childhood cancer survivors. Nat Clin Pract Oncol 4:334–335

    Article  PubMed  Google Scholar 

  16. Lipshultz SE, Alvarez JA, Scully RE (2008) Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525–533

    Article  CAS  PubMed  Google Scholar 

  17. Lipshultz SE, Miller TL, Scully RE et al (2012) Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 30:1042–1049

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Clark EB (1990) Growth, morphogenesis, and function: the dynamics of heart development. In: Moller JH, Neal WA, Lock JE (eds) Fetal, neonatal, and infant heart disease. Appleton-Century-Crofts, New York

    Google Scholar 

  19. Clark EB, Hu N, Frommelt P et al (1989) Effect of increased pressure on ventricular growth in stage 21 chick embryos. Am J Physiol 257:H55–H61

    CAS  PubMed  Google Scholar 

  20. Fishman NH, Hof RB, Rudolph AM et al (1978) Models of congenital heart disease in fetal lambs. Circulation 58:354–364

    Article  CAS  PubMed  Google Scholar 

  21. Lipshultz SE, Colan SD, Gelber RD et al (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815

    Article  CAS  PubMed  Google Scholar 

  22. Billingham ME (1991) Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver MD (ed) Cardiovascular pathology. Churchill Livingstone, New York

    Google Scholar 

  23. Tokarska-Schlattner M, Zaugg M, Zuppinger C et al (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389–405

    Article  CAS  PubMed  Google Scholar 

  24. Brouwer CA, Postma A, Vonk JM et al (2011) Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. Eur J Cancer 47:2453–2462

    Article  PubMed  Google Scholar 

  25. Minotti G, Menna P, Salvatorelli E et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229

    Article  CAS  PubMed  Google Scholar 

  26. Senkus E, Jassem J (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37:300–311

    Article  CAS  PubMed  Google Scholar 

  27. Nicolay K, van der Neut R, Fok JJ et al (1985) Effects of adriamycin on lipid polymorphism in cardiolipin-containing model and mitochondrial membranes. Biochim Biophys Acta 819:55–65

    Article  CAS  PubMed  Google Scholar 

  28. Leonard RC, Williams S, Tulpule A et al (2009) Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 18:218–224

    Article  CAS  PubMed  Google Scholar 

  29. Kalyanaraman B, Joseph J, Kalivendi S et al (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234–235:119–124

    Article  PubMed  Google Scholar 

  30. De Angelis A, Piegari E, Cappetta D et al (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121:276–292

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Thompson KL, Rosenzweig BA, Zhang J et al (2010) Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 66:303–314

    Article  CAS  PubMed  Google Scholar 

  32. Olson RD, Li X, Palade P et al (2000) Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol 169:168–176

    Article  CAS  PubMed  Google Scholar 

  33. Outomuro D, Grana DR, Azzato F et al (2007) Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol 117:6–15

    Article  PubMed  Google Scholar 

  34. Goormaghtigh E, Huart P, Praet M et al (1990) Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 35:247–257

    Article  CAS  PubMed  Google Scholar 

  35. Adachi K, Fujiura Y, Mayumi F et al (1993) A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun 195:945–951

    Article  CAS  PubMed  Google Scholar 

  36. Lebrecht D, Walker UA (2007) Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 7:108–113

    Article  CAS  PubMed  Google Scholar 

  37. Braverman AC, Antin JH, Plappert MT et al (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215–1223

    CAS  PubMed  Google Scholar 

  38. Kupari M, Volin L, Suokas A et al (1990) Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 5:91–98

    CAS  PubMed  Google Scholar 

  39. Gottdiener JS, Appelbaum FR, Ferrans VJ et al (1981) Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141:758–763

    Article  CAS  PubMed  Google Scholar 

  40. Friedman HS, Colvin OM, Aisaka K et al (1990) Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 50:2455–2462

    CAS  PubMed  Google Scholar 

  41. Quezado ZM, Wilson WH, Cunnion RE et al (1993) High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118:31–36

    Article  CAS  PubMed  Google Scholar 

  42. Kandylis K, Vassilomanolakis M, Tsoussis S et al (1989) Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 24:395–396

    CAS  PubMed  Google Scholar 

  43. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225

    Article  CAS  PubMed  Google Scholar 

  44. Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916

    Article  PubMed  CAS  Google Scholar 

  45. Daves M, Dixit A, Sankaran H et al (2011) No increased risk of cardiotoxicity in pediatric patients with leukemia imatinib therapy. Pediatr Blood Cancer 56:925

    Google Scholar 

  46. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247

    Article  CAS  PubMed  Google Scholar 

  47. Floyd JD, Nguyen DT, Lobins RL et al (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685–7696

    Article  CAS  PubMed  Google Scholar 

  48. Rowinsky EK, McGuire WP, Guarnieri T et al (1991) Cardiac disturbances during the administration of taxol. J Clin Oncol 9:1704–1712

    CAS  PubMed  Google Scholar 

  49. Adams MJ, Hardenbergh PH, Constine LS et al (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75

    Article  PubMed  Google Scholar 

  50. Stewart JR, Fajardo LF (1984) Radiation-induced heart disease: an update. Prog Cardiovasc Dis 27:173–194

    Article  CAS  PubMed  Google Scholar 

  51. Fajardo LF, Stewart JR, Cohn KE (1968) Morphology of radiation-induced heart disease. Arch Pathol 86:512–519

    CAS  PubMed  Google Scholar 

  52. Chello M, Mastroroberto P, Romano R et al (1996) Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg 4:222–226

    Article  CAS  PubMed  Google Scholar 

  53. Orzan F, Brusca A, Gaita F et al (1993) Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol 39:151–156

    Article  CAS  PubMed  Google Scholar 

  54. Cohen SI, Bharati S, Glass J et al (1981) Radiotherapy as a cause of complete atrioventricular block in Hodgkin’s disease. An electrophysiological-pathological correlation. Arch Intern Med 141:676–679

    Article  CAS  PubMed  Google Scholar 

  55. La Vecchia L (1996) Physiologic dual chamber pacing in radiation-induced atrioventricular block. Chest 110:580–581

    Article  PubMed  Google Scholar 

  56. Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511

    Article  PubMed  Google Scholar 

  57. Schultz-Hector S, Trott KR (2007) Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 67:10–18

    Article  CAS  PubMed  Google Scholar 

  58. Little MP, Tawn EJ, Tzoulaki I et al (2008) A systematic review of epidemiological associations between low and moderate doses of ionizing radiation and late cardiovascular effects, and their possible mechanisms. Radiat Res 169:99–109

    Article  CAS  PubMed  Google Scholar 

  59. Robbins ME, Zhao W (2004) Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol 80:251–259

    Article  CAS  PubMed  Google Scholar 

  60. Brosius FC 3rd, Waller BF, Roberts WC (1981) Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 70:519–530

    Article  PubMed  Google Scholar 

  61. Veinot JP, Edwards WD (1996) Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 27:766–773

    Article  CAS  PubMed  Google Scholar 

  62. Carlson RG, Mayfield WR, Normann S et al (1991) Radiation-associated valvular disease. Chest 99:538–545

    Article  CAS  PubMed  Google Scholar 

  63. McEniery PT, Dorosti K, Schiavone WA et al (1987) Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 60:1020–1024

    Article  CAS  PubMed  Google Scholar 

  64. King V, Constine LS, Clark D et al (1996) Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 36:881–889

    Article  CAS  PubMed  Google Scholar 

  65. Joensuu H (1993) Myocardial infarction after irradiation in Hodgkin’s disease: a review. Recent Results Cancer Res 130:157–173

    Article  CAS  PubMed  Google Scholar 

  66. Yusuf SW, Sami S, Daher IN (2011) Radiation-induced heart disease: a clinical update. Cardiol Res Pract 2011:317659

    PubMed Central  PubMed  Google Scholar 

  67. Adams MJ, Lipshultz SE (2005) Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 44:600–606

    Article  PubMed  Google Scholar 

  68. Nousiainen T, Vanninen E, Rantala A et al (1999) QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin’s lymphoma. J Intern Med 245:359–364

    Article  CAS  PubMed  Google Scholar 

  69. Giantris A, Abdurrahman L, Hinkle A et al (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27:53–68

    Article  CAS  PubMed  Google Scholar 

  70. Krischer JP, Epstein S, Cuthbertson DD et al (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15:1544–1552

    CAS  PubMed  Google Scholar 

  71. Barry E, Alvarez JA, Scully RE et al (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 8:1039–1058

    Article  CAS  PubMed  Google Scholar 

  72. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72–85

    CAS  PubMed  Google Scholar 

  73. Diamond MB, Franco VI, Miller TL et al (2012) Preventing and treating anthracycline-related cardiotoxicity in survivors of childhood cancer. Curr Cancer Ther Rev 8:141–151

    Article  CAS  Google Scholar 

  74. Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34:1102–1111

    Google Scholar 

  75. Curigliano G, Mayer EL, Burstein HJ et al (2010) Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 53:94–104

    Article  CAS  PubMed  Google Scholar 

  76. Kim DH, Landry AB 3rd, Lee YS et al (1989) Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 21:433–436

    Article  CAS  PubMed  Google Scholar 

  77. Ali MK, Ewer MS, Gibbs HR et al (1994) Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer 74:182–188

    Article  CAS  PubMed  Google Scholar 

  78. Lipshultz SE, Colan SD, Sanders SP et al (1989) Cardiac mechanics after growth hormone therapy in pediatric adriamycin recipients. Pediatr Res 25:153A

    Google Scholar 

  79. Steinherz LJ, Steinherz PG, Tan C (1995) Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24:352–361

    Article  CAS  PubMed  Google Scholar 

  80. Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677

    Article  CAS  PubMed  Google Scholar 

  81. Lipshultz SE, Lipsitz SR, Mone SM et al (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743

    Article  CAS  PubMed  Google Scholar 

  82. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717

    Article  Google Scholar 

  83. Krischer JP, Cuthbertson DD, Epstein S et al (1997) Risk Factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience. Prog Pediatr Cardiol 8:83–90

    Article  Google Scholar 

  84. Green DM, Grigoriev YA, Nan B et al (2001) Congestive heart failure after treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study group. J Clin Oncol 19:1926–1934

    CAS  PubMed  Google Scholar 

  85. Bristow MR, Mason JW, Billingham ME et al (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168–175

    Article  CAS  PubMed  Google Scholar 

  86. Cortes EP, Lutman G, Wanka J et al (1975) Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother Rep 6:215–225

    Google Scholar 

  87. Trachtenberg BH, Landy DC, Franco VI et al (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342–353

    Article  PubMed  Google Scholar 

  88. Gupta M, Steinherz PG, Cheung NK et al (2003) Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 40:343–347

    Article  PubMed  Google Scholar 

  89. Wouters KA, Kremer LC, Miller TL et al (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561–578

    Article  CAS  PubMed  Google Scholar 

  90. Lipshultz SE, Miller TL, Lipsitz SR et al (2010) Late cardiac status in long-term survivors of childhood high-risk all 8 years after continuous or bolus infusion of doxorubicin: the DFCI childhood ALL 91-01 randomized trial. J Clin Oncol 28(9513):2010

    Google Scholar 

  91. Lipshultz SE, Giantris AL, Lipsitz SR et al (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 20:1677–1682

    Article  CAS  PubMed  Google Scholar 

  92. Lipshultz SE, Miller TL, Lipsitz SR et al (2012) Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 130:1003–1011

    Article  PubMed Central  PubMed  Google Scholar 

  93. Levitt GA, Dorup I, Sorensen K et al (2004) Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 124:463–468

    Article  CAS  PubMed  Google Scholar 

  94. Cattel L, Ceruti M, Dosio F (2003) From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89:237–249

    CAS  PubMed  Google Scholar 

  95. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54(Suppl 4):15–21

    Article  CAS  PubMed  Google Scholar 

  96. O’Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449

    Article  PubMed  Google Scholar 

  97. Berry G, Billingham M, Alderman E et al (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711–716

    Article  CAS  PubMed  Google Scholar 

  98. Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029–1033

    Article  CAS  PubMed  Google Scholar 

  99. Trudeau M, Pagani O (2001) Epirubicin in combination with the taxanes. Semin Oncol 28:41–50

    Article  CAS  PubMed  Google Scholar 

  100. Chan S, Davidson N, Juozaityte E et al (2004) Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 15:1527–1534

    Article  CAS  PubMed  Google Scholar 

  101. Lahtinen R, Kuikka J, Nousiainen T et al (1991) Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 46:301–305

    Article  CAS  PubMed  Google Scholar 

  102. Anderlini P, Benjamin RS, Wong FC et al (1995) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13:2827–2834

    CAS  PubMed  Google Scholar 

  103. Cohen BA, Mikol DD (2004) Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 63:S28–S32

    Article  CAS  PubMed  Google Scholar 

  104. Chen T, Zhou G, Zhu Q et al (2010) Overexpression of vascular endothelial growth factor 165 (VGEF165) protects cardiomyocytes against doxorubicin-induced apoptosis. J Chemother 22:402–406

    Article  CAS  PubMed  Google Scholar 

  105. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  CAS  PubMed  Google Scholar 

  106. Filopei J, Frishman W (2012) Radiation-induced heart disease. Cardiol Rev 20:184–188

    Article  PubMed  Google Scholar 

  107. Sorensen K, Levitt GA, Bull C et al (2003) Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97:1991–1998

    Article  CAS  PubMed  Google Scholar 

  108. Adams MJ, Lipsitz SR, Colan SD et al (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139–3148

    Article  PubMed  Google Scholar 

  109. Glanzmann C, Huguenin P, Lutolf UM et al (1994) Cardiac lesions after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 30:43–54

    Article  CAS  PubMed  Google Scholar 

  110. Kreuser ED, Voller H, Behles C et al (1993) Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin’s disease. Br J Haematol 84:615–622

    Article  CAS  PubMed  Google Scholar 

  111. Gustavsson A, Eskilsson J, Landberg T et al (1990) Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann Oncol 1:355–363

    CAS  PubMed  Google Scholar 

  112. Lund MB, Ihlen H, Voss BM et al (1996) Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin’s disease: an echocardiographic study. Heart 75:591–595

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  113. Darby SC, Cutter DJ, Boerma M et al (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76:656–665

    Article  PubMed Central  PubMed  Google Scholar 

  114. Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270:1949–1955

    Article  CAS  PubMed  Google Scholar 

  115. Weber DC, Peguret N, Dipasquale G et al (2009) Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 75:1578–1586

    Article  PubMed  Google Scholar 

  116. Maraldo MV, Brodin NP, Vogelius IR et al (2012) Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 83:1232–1237

    Article  PubMed  Google Scholar 

  117. Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin’s disease. An analysis of technique, tumor eradication, and complications. Cancer 37:2813–2825

    Article  CAS  PubMed  Google Scholar 

  118. Specht L, Yahalom J, Illidge T et al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862

    Google Scholar 

  119. Chen MH, Cash EP, Danias PG et al (2002) Respiratory maneuvers decrease irradiated cardiac volume in patients with left-sided breast cancer. J Cardiovasc Magn Reson 4:265–27

    Article  PubMed  Google Scholar 

  120. Abosoudah I, Greenberg ML, Ness KK et al (2011) Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors. Pediatr Blood Cancer 57:467–472

    Article  PubMed  Google Scholar 

  121. Mertens AC, Liu Q, Neglia JP et al (2008) Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 100:1368–1379

    Article  PubMed Central  PubMed  Google Scholar 

  122. Landy DC, Miller TL, Lopez-Mitnik G et al (2012) Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Am Heart J 163:295–301.e292

    Article  PubMed Central  PubMed  Google Scholar 

  123. Mulrooney DA, Yeazel MW, Kawashima T et al (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606

    Article  PubMed Central  PubMed  Google Scholar 

  124. Mavinkurve-Groothuis AM, Groot-Loonen J, Marcus KA et al (2010) Myocardial strain and strain rate in monitoring subclinical heart failure in asymptomatic long-term survivors of childhood cancer. Ultrasound Med Biol 36:1783–1791

    Article  PubMed  Google Scholar 

  125. Lawless SC, Verma P, Green DM et al (2007) Mortality experiences among 15+ year survivors of childhood and adolescent cancers. Pediatr Blood Cancer 48:333–338

    Article  PubMed  Google Scholar 

  126. Shankar SM, Marina N, Hudson MM et al (2008) Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 121:e387–e396

    Article  PubMed  Google Scholar 

  127. Steinherz LJ, Graham T, Hurwitz R et al (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89:942–949

    CAS  PubMed  Google Scholar 

  128. Adams MJ, Lipshultz SE, Schwartz C et al (2003) Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 13:346–356

    Article  PubMed  Google Scholar 

  129. Children’s Oncology Group (2012) Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. www.survivorshipguidelines.org. Accessed 20 Apr 2012

  130. Lipshultz SE, Vlach SA, Lipsitz SR et al (2005) Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115:1613–1622

    Article  PubMed  Google Scholar 

  131. Postma A, Bink-Boelkens MT, Beaufort-Krol GC et al (1996) Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 26:230–237

    Article  CAS  PubMed  Google Scholar 

  132. van Dalen EC, van der Pal HJ, van den Bos C et al (2006) Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. Eur J Cancer 42:2549–2553

    Article  PubMed  CAS  Google Scholar 

  133. Lipshultz SE, Sanders SP, Goorin AM et al (1994) Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433–437

    CAS  PubMed  Google Scholar 

  134. Lipshultz SE, Schaechter J, Carrillo A et al (2012) Can the consequences of universal cholesterol screening during childhood prevent cardiovascular disease and thus reduce long-term health care costs? Pediatr Endocrinol Rev 9:698–705

    PubMed  Google Scholar 

  135. Heidenreich PA, Schnittger I, Strauss HW et al (2007) Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 25:43–49

    Article  PubMed  Google Scholar 

  136. Hancock SL (1998) Cardiac toxicity after cancer therapy. Research issues in Cancer Survivorship Meeting. National Cancer Institute, Bethesda

    Google Scholar 

  137. Bluemke DA, Achenbach S, Budoff M et al (2008) Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the american heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young. Circulation 118:586–606

    Article  PubMed  Google Scholar 

  138. Orzan F, Brusca A, Conte MR et al (1993) Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 69:496–500

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  139. Lipshultz SE, Colan SD (1993) The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients. In: Bricker JT, Green DM, D’Angio GJ (eds) Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, New York

    Google Scholar 

  140. Colan SD, Borow KM, Neumann A (1984) Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol 4:715–724

    Article  CAS  PubMed  Google Scholar 

  141. van der Pal HJ, van Dalen EC, Hauptmann M et al (2010) Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 170:1247–1255

    PubMed  Google Scholar 

  142. Sieswerda E, Kremer LC, Vidmar S et al (2010) Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study. Pediatr Blood Cancer 54:579–584

    PubMed  Google Scholar 

  143. Jurcut R, Wildiers H, Ganame J et al (2008) Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 21:1283–1289

    Article  PubMed  Google Scholar 

  144. Hare JL, Brown JK, Leano R et al (2009) Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 158:294–301

    Article  CAS  PubMed  Google Scholar 

  145. Sawaya H, Sebag IA, Plana JC et al (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107:1375–1380

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  146. Lipshultz SE, Cochran TR, Wilkinson JD (2012) Screening for long-term cardiac status during cancer treatment. Circ Cardiovasc Imaging 5:555–558

    Article  PubMed  Google Scholar 

  147. Karakurt C, Kocak G, Ozgen U (2008) Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 25:880–887

    Article  PubMed  Google Scholar 

  148. Iarussi D, Pisacane C, Indolfi P et al (2005) Evaluation of left ventricular function in long-term survivors of childhood Hodgkin disease. Pediatr Blood Cancer 45:700–705

    Article  PubMed  Google Scholar 

  149. Brouwer CA, Gietema JA, van den Berg MP et al (2006) Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol 17:1586–1591

    Article  CAS  PubMed  Google Scholar 

  150. Wong FL, Bhatia S, Kurian S et al (2012) Cost-effectiveness of the Children’s Oncology Group (COG) Long-term Follow-up (LTFU) guidelines in reducing the risk of Congestive Heart Failure (CHF) in long-term Childhood Cancer Survivors (CSS). ASCO annual meeting, Chicago

    Google Scholar 

  151. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L et al (2009) Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer 52:631–636

    Article  PubMed  Google Scholar 

  152. Simbre VC, Duffy SA, Dadlani GH et al (2005) Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 7:187–202

    Article  PubMed  Google Scholar 

  153. Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582

    Article  CAS  PubMed  Google Scholar 

  154. Lipshultz SE, Landy DC, Lopez-Mitnik G et al (2012) Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 30:1050–1057

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  155. Larsen RL, Barber G, Heise CT et al (1992) Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics 89:722–729

    CAS  PubMed  Google Scholar 

  156. Schwartz CL, Hobbie WL, Truesdell S et al (1993) Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 11:1906–1910

    CAS  PubMed  Google Scholar 

  157. Weesner KM, Bledsoe M, Chauvenet A et al (1991) Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 68:435–438

    Article  CAS  PubMed  Google Scholar 

  158. Correa CR, Litt HI, Hwang WT et al (2007) Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 25:3031–3037

    Article  PubMed  Google Scholar 

  159. Mancini DM, Eisen H, Kussmaul W et al (1991) Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778–786

    Article  CAS  PubMed  Google Scholar 

  160. De Caro E, Smeraldi A, Trocchio G et al (2011) Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors. Pediatr Blood Cancer 56:122–126

    Article  PubMed  Google Scholar 

  161. Boivin JF, Hutchison GB, Lubin JH et al (1992) Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer 69:1241–1247

    Article  CAS  PubMed  Google Scholar 

  162. Hancock SL, Donaldson SS, Hoppe RT (1993) Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 11:1208–1215

    CAS  PubMed  Google Scholar 

  163. Campbell J, King SBI, Douglas JSJ et al (1985) Prevalence and distribution of disease in patients catheterized for suspected coronary disease. McGraw-Hill, New York

    Google Scholar 

  164. Lind PA, Pagnanelli R, Marks LB et al (2003) Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys 55:914–920

    Article  PubMed  Google Scholar 

  165. Waller BF (2011) Non-atherosclerotic coronary heart disease. McGraw-Hill, York New

    Google Scholar 

  166. Wethal T, Lund MB, Edvardsen T et al (2009) Valvular dysfunction and left ventricular changes in Hodgkin’s lymphoma survivors. A longitudinal study. Br J Cancer 101:575–581

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  167. Schultz-Hector S, Balz K (1994) Radiation-induced loss of endothelial alkaline phosphatase activity and development of myocardial degeneration. An ultrastructural study. Lab Invest 71:252–260

    CAS  PubMed  Google Scholar 

  168. Heidenreich PA, Hancock SL, Lee BK et al (2003) Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42:743–749

    Article  PubMed  Google Scholar 

  169. Nishimura RA, Carabello BA, Faxon DP et al (2008) ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52:676–685

    Article  PubMed  Google Scholar 

  170. Lee PJ, Mallik R (2005) Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev 13:80–86

    Article  PubMed  Google Scholar 

  171. Smith AL, Book WM (2011) Effect of noncardiac drugs, electricity, poison and radiation on the heart. In: Fuster V, Walsh RA, Harrington RA (eds) Hurst’s the heart, 13th edn. McGraw Hill, New York

    Google Scholar 

  172. Greenwood RD, Rosenthal A, Cassady R et al (1974) Constrictive pericarditis in childhood due to mediastinal irradiation. Circulation 50:1033–1039

    Article  CAS  PubMed  Google Scholar 

  173. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879

    Article  CAS  PubMed  Google Scholar 

  174. Silber JH, Jakacki RI, Larsen RL et al (1993) Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21:477–479

    Article  CAS  PubMed  Google Scholar 

  175. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321–1327

    CAS  PubMed  Google Scholar 

  176. Wang L, Weinshilboum R (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25:1629–1638

    Article  CAS  PubMed  Google Scholar 

  177. Deng S, Wojnowski L (2007) Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 7:129–134

    Article  CAS  PubMed  Google Scholar 

  178. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al (2008) Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789–2795

    Article  PubMed  Google Scholar 

  179. Lipshultz SE, Lipsitz SR, Kutok JL et al (2013) Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 119:3555–3562

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  180. Miranda CJ, Makui H, Soares RJ et al (2003) Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102:2574–2580

    Article  CAS  PubMed  Google Scholar 

  181. Qureshi MY, Wilkinson JD, Lipshultz SE (2012) The relationship of childhood obesity with cardiomyopathy and heart failure. In: Lipshultz SE, Miller TL, Messiah SE (eds) Pediatric metabolic syndrome: comprehensive clinical review and related health issues. Springer Verlag London Ltd, London; acting in cooperation with Springer-Verlag GmbH Berlin Heidelberg, Spring Science and Business Media LLC New York and Springer Japan KK

    Google Scholar 

  182. Brown SR, Lipshultz SE (2012) Childhood metabolic syndrome and cancer risk. In: Lipshultz SE, Miller TL, Messiah SE (eds) Pediatric metabolic syndrome: comprehensive clinical review and related health issues. Springer Verlag London Ltd, London; acting in cooperation with Springer-Verlag GmbH Berlin Heidelberg, Spring Science and Business Media LLC New York and Springer Japan KK

    Google Scholar 

  183. Franks PW, Hanson RL, Knowler WC et al (2010) Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 362:485–493

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  184. Sumner AD, Khalil YK, Reed JF 3rd (2012) The relationship of peripheral arterial disease and metabolic syndrome prevalence in asymptomatic US adults 40 years and older: results from the National Health and Nutrition Examination Survey (1999–2004). J Clin Hypertens (Greenwich) 14:144–148

    Article  CAS  Google Scholar 

  185. Siviero-Miachon AA, Monteiro CM, Pires LV et al (2011) Early traits of metabolic syndrome in pediatric post-cancer survivors: outcomes in adolescents and young adults treated for childhood medulloblastoma. Arq Bras Endocrinol Metabol 55:653–660

    Article  PubMed  Google Scholar 

  186. Sohn YB, Kim SJ, Park SW et al (2011) The metabolic syndrome and body composition in childhood cancer survivors. Korean J Pediatr 54:253–259

    Article  PubMed Central  PubMed  Google Scholar 

  187. Lipshultz SE, Wilkinson JD, Messiah SE et al (2009) Clinical research directions in pediatric cardiology. Curr Opin Pediatr 21:585–593

    Article  PubMed Central  PubMed  Google Scholar 

  188. Wasilewski-Masker K, Kaste SC, Hudson MM et al (2008) Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics 121:e705–e713

    Article  PubMed  Google Scholar 

  189. Hudson MM, Mertens AC, Yasui Y et al (2003) Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 290:1583–1592

    Article  CAS  PubMed  Google Scholar 

  190. Mattano LA Jr, Sather HN, Trigg ME et al (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol 18:3262–3272

    PubMed  Google Scholar 

  191. Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53:e1–e90

    Article  PubMed  Google Scholar 

  192. Miller TL, Lipsitz SR, Lopez-Mitnik G et al (2010) Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 19:2013–2022

    Article  PubMed  Google Scholar 

  193. Cosson E, Hamo-Tchatchouang E, Banu I et al (2010) A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. Diabetes Metab 36:312–318

    Article  CAS  PubMed  Google Scholar 

  194. Klosky JL, Howell CR, Li Z et al (2012) Risky health behavior among adolescents in the childhood cancer survivor study cohort. J Pediatr Psychol 37:634–646

    Article  PubMed Central  PubMed  Google Scholar 

  195. Kenney LB, Nancarrow CM, Najita J et al (2010) Health status of the oldest adult survivors of cancer during childhood. Cancer 116:497–505

    Article  PubMed  Google Scholar 

  196. Lipshultz SE, Lipsitz SR, Sallan SE (2003) Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence: in reply (letter). J Clin Oncol 21:3377–3378

    Article  Google Scholar 

  197. Levit G, Bunch K, Rogers CA et al (1996) Cardiac transplantation in childhood cancer survivors in Great Britain. Eur J Cancer 32A:826–830

    Article  Google Scholar 

  198. Levitt G, Anazodo A, Burch M et al (2009) Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur J Cancer 45:3027–3034

    Article  PubMed  Google Scholar 

  199. Silber JH, Cnaan A, Clark BJ et al (2004) Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22:820–828

    Article  CAS  PubMed  Google Scholar 

  200. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators (1991) N Engl J Med 325:293–302

    Google Scholar 

  201. Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474–2481

    Article  CAS  PubMed  Google Scholar 

  202. Lipshultz SE, Lipsitz SR, Sallan SE et al (2002) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20:4517–4522

    Article  CAS  PubMed  Google Scholar 

  203. Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385–1390

    Article  CAS  PubMed  Google Scholar 

  204. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999) Lancet 353:2001–2007

    Google Scholar 

  205. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial (1999) Lancet 353:9–13

    Google Scholar 

  206. Colucci WS, Packer M, Bristow MR et al (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 94:2800–2806

    Article  CAS  PubMed  Google Scholar 

  207. Eichhorn EJ, Bristow MR (2001) The carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2:20–23

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  208. Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194–2199

    Article  PubMed  Google Scholar 

  209. Poole-Wilson PA, Swedberg K, Cleland JG et al (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13

    Article  CAS  PubMed  Google Scholar 

  210. Noori P, Hou SM (2001) Mutational spectrum induced by acetaldehyde in the HPRT gene of human T lymphocytes resembles that in the p53 gene of esophageal cancers. Carcinogenesis 22:1825–1830

    Article  CAS  PubMed  Google Scholar 

  211. Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258–2262

    Article  CAS  PubMed  Google Scholar 

  212. Domanski MJ, Borkowf CB, Campeau L et al (2000) Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. J Am Coll Cardiol 36:1877–1883

    Article  CAS  PubMed  Google Scholar 

  213. Flather MD, Shibata MC, Coats AJ et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225

    Article  CAS  PubMed  Google Scholar 

  214. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure (2001) N Engl J Med 344:1659–1667

    Google Scholar 

  215. Albouaini K, Andron M, Alahmar A et al (2007) Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2:535–540

    PubMed Central  PubMed  Google Scholar 

  216. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717

    Article  CAS  PubMed  Google Scholar 

  217. Carson P, Ziesche S, Johnson G et al (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5:178–187

    Article  CAS  PubMed  Google Scholar 

  218. Taylor AL, Ziesche S, Yancy C et al (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:2049–2057

    Article  CAS  PubMed  Google Scholar 

  219. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group (1997) N Engl J Med 336:525–533

    Google Scholar 

  220. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302

    Article  CAS  PubMed  Google Scholar 

  221. Lipshultz SE, Miller TL, Gerschenson M et al (2012) Impaired mitochondrial structure and function which is abrogated by dexrazoxane in doxorubicin-treated childhood ALL survivors. ASCO Annual meeting, Chicago

    Google Scholar 

  222. Davidson N (2011) Preserving cardiac health in the breast cancer patient treated with anthracyclines. In: Olver IN (ed) The MASCC textbook of cancer supportive care and survivorship. Springer, New York/London

    Google Scholar 

  223. Swain SM, Whaley FS, Gerber MC et al (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318–1332

    CAS  PubMed  Google Scholar 

  224. Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153

    Article  CAS  PubMed  Google Scholar 

  225. Asselin B, Devidas M, Zhou T et al (2012) Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). ASCO annual meeting, Chicago

    Google Scholar 

  226. Hensley ML, Hagerty KL, Kewalramani T et al (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27:127–145

    Article  CAS  PubMed  Google Scholar 

  227. Grdina DJ, Kataoka Y, Murley JS (2000) Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact 16:237–279

    CAS  PubMed  Google Scholar 

  228. Nazeyrollas P, Frances C, Prevost A et al (2003) Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment. Anticancer Res 23:405–409

    CAS  PubMed  Google Scholar 

  229. Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A et al (2007) Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 24:403–408

    Article  CAS  PubMed  Google Scholar 

  230. Eaton S, Skinner R, Hale JP et al (2000) Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 302:1–9

    Article  CAS  PubMed  Google Scholar 

  231. Conklin KA (2005) Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 4:110–130

    Article  CAS  PubMed  Google Scholar 

  232. Ranasarma T, Slavik M, Muggia FM (1985) Natural occurrence distribution of coenzyme Q. Wiley, Chichester

    Google Scholar 

  233. Okuma K, Ota K (1986) The effect of coenzyme Q10 on ECG changes induced by doxorubicin (Adiramycin). Elsevier/North-Holland Biomedical Press, Amsterdam

    Google Scholar 

  234. Danesi F, Malaguti M, Nunzio MD et al (2006) Counteraction of adriamycin-induced oxidative damage in rat heart by selenium dietary supplementation. J Agric Food Chem 54:1203–1208

    Article  CAS  PubMed  Google Scholar 

  235. Bjelakovic G, Nikolova D, Gluud LL et al (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297:842–857

    Article  CAS  PubMed  Google Scholar 

  236. Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883

    Article  PubMed  Google Scholar 

  237. Abraham WT, Hayes DL (2003) Cardiac resynchronization therapy for heart failure. Circulation 108:2596–2603

    Article  PubMed  Google Scholar 

  238. Cleland JG, Daubert JC, Erdmann E et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539–1549

    Article  CAS  PubMed  Google Scholar 

  239. Pagani FD, Miller LW, Russell SD et al (2009) Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 54:312–321

    Article  PubMed  Google Scholar 

  240. Dillon TA, Sullivan M, Schatzlein MH et al (1991) Cardiac transplantation in patients with preexisting malignancies. Transplantation 52:82–85

    Article  CAS  PubMed  Google Scholar 

  241. Ewer MS, Jaffe N, Ried H et al (1998) Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol 31:512–515

    Article  CAS  PubMed  Google Scholar 

  242. Casper ES, Gaynor JJ, Hajdu SI et al (1991) A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 68:1221–1229

    Article  CAS  PubMed  Google Scholar 

  243. Lipshultz SE, Adams MJ (2010) Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol 28:1276–1281

    Article  PubMed  Google Scholar 

  244. Lipshultz SE, Cochran TR, Franco VI, Miller TL (2013) Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol 10:697–710

    Article  CAS  PubMed  Google Scholar 

  245. Lipshultz SE, Adams MJ, Colan SD et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults Who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128:1927–1995

    Article  PubMed  Google Scholar 

  246. Kenney LB, Bradeen H, Kadan-Lottick NS et al (2011) The current status of follow-up services for childhood cancer survivors, are we meeting goals and expectations: a report from the Consortium of New England Childhood Cancer Survivors. Pediatr Blood Cancer 57:1062–1066

    Article  PubMed  Google Scholar 

  247. Blanco JG, Sun CL, Landier W et al (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children’s Oncology Group. J Clin Oncol 30:1415–1421

    Google Scholar 

  248. van der Pal HJ, van Dalen EC, van Delden E et al (2012) High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30:1429–1437

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children’s Heart Center, The Children’s Hospital at Montefiore/Albert Einstein College of Medicine, 3415 Bainbridge Avenue, R-1, Bronx, NY, 10467, USA

    David A. Briston MD

  2. University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA

    Thomas R. Cochran

  3. Division of Pediatric Cardiology, New York-Presbyterian/Morgan Stanley Children’s Hospital, 3959 Broadway #517;, New York, NY, 10032, USA

    Peter J. Sambatakos MD

  4. Departments of Internal Medicine and Pediatrics, University of Miami Miller School of Medicine, 1611 NW 12th Avenue C600D, Miami, FL, 33136, USA

    Stefanie R. Brown MD

  5. Medicine (Cardiology), Oncology, Obstetrics and Gynecology, Molecular Biology and Genetics, Family Medicine and Public Health Sciences, and Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA

    Steven E. Lipshultz MD, FAAP, FAHA

  6. Center for Urban Responses to Environmental Stressors, Wayne State University School of Medicine, Detroit, MI, USA

    Steven E. Lipshultz MD, FAAP, FAHA

  7. Carman and Ann Adams Department of Pediatrics, Children’s Research Center of Michigan, Children’s Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA

    Steven E. Lipshultz MD, FAAP, FAHA

  8. NCI-designated Comprehensive Cancer Center, Karmanos Cancer Institute, 3901 Beaubien Boulevard, 1K40, Detroit, MI, 48201-2196, USA

    Steven E. Lipshultz MD, FAAP, FAHA

Authors
  1. David A. Briston MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas R. Cochran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter J. Sambatakos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefanie R. Brown MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven E. Lipshultz MD, FAAP, FAHA
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, MD Anderson Cancer Center, Houston, Texas, USA

    Cindy L. Schwartz

  2. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Wendy L. Hobbie

  3. Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, James P. Wilmot Cancer Ctr, Rochester, New York, USA

    Louis S. Constine

  4. Center for Cancer And Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA

    Kathleen S. Ruccione

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Briston, D.A., Cochran, T.R., Sambatakos, P.J., Brown, S.R., Lipshultz, S.E. (2015). Cardiovascular Effects of Cancer Therapy. In: Schwartz, C., Hobbie, W., Constine, L., Ruccione, K. (eds) Survivors of Childhood and Adolescent Cancer. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-16435-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16435-9_10

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16434-2

  • Online ISBN: 978-3-319-16435-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation